Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Lumito

0.02 SEK

+6.67 %

Less than 1K followers

LUMITO

Nordic SME

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+6.67 %
+14.29 %
0.00 %
-69.23 %
-91.12 %
-90.88 %
-96.99 %
-98.95 %
-96.72 %

Lumito is a Swedish company that develops and markets systems for tissue and biomarker analysis in digital pathology, built on upconverting nanoparticle technology. The company targets healthcare facilities, research and the pharmaceutical sector. The company was formed in 2010 as a spinoff from a research group at Lund University's Department of Atomic Physics and Laser Center. Lumito is headquartered in Lund.

Read more
Market cap
27.53M SEK
Turnover
262.32K SEK
Revenue
100K
EBIT %
-38,300 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
20/2
2026

Annual report '25

7/5
2026

General meeting '26

7/5
2026

Interim report Q1'26

All
Press releases
3rd party
ShowingAll content types
Regulatory press release20 hours ago

Lumito erhåller godkännande av patent i Indien

Lumito
Regulatory press release20 hours ago

Lumito receives patent approval in India

Lumito
Regulatory press releaseyesterday

Två svenska forskningskunder lägger order på Lumitos SCIZYS Erbium kit

Lumito

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press releaseyesterday

Two Swedish research customers place orders for Lumito’s SCIZYS Erbium Kit

Lumito
Regulatory press release1/23/2026, 1:50 PM

Lumitos teknologi presenterad vid The Pathological Society of Great Britain & Ireland Winter Meeting 2026

Lumito
Regulatory press release1/23/2026, 1:50 PM

Lumito’s technology presented at The Pathological Society of Great Britain & Ireland Winter Meeting 2026

Lumito
Regulatory press release1/20/2026, 3:30 PM

Changes to the Nomination Committee ahead of Lumito’s Annual General Meeting 2026

Lumito
Regulatory press release1/20/2026, 3:30 PM

Förändringar i valberedningen inför Lumitos årsstämma 2026

Lumito
Regulatory press release1/20/2026, 9:55 AM

Extra bolagsstämma i Lumito AB (publ) den 20 januari 2026

Lumito
Press release1/15/2026, 1:15 PM

Kalqyl: Lumito: NGM Company Insights

Lumito
Regulatory press release1/13/2026, 8:30 AM

Analyst Group inleder bevakning av Lumito

Lumito
Regulatory press release1/13/2026, 8:30 AM

Analyst Group initiates coverage of Lumito

Lumito
Press release1/12/2026, 12:43 PM

Analyst Group: Analyst Group inleder analysbevakning av Lumito

Lumito
Regulatory press release1/12/2026, 8:15 AM

Lumito erhåller order från svensk forskningsenhet

Lumito
Regulatory press release1/12/2026, 8:15 AM

Lumito receives order from Swedish research unit

Lumito
Regulatory press release1/8/2026, 12:00 PM

Lumito publicerar investerarbrev – 2025 i backspegeln och vägen framåt

Lumito
Regulatory press release1/8/2026, 12:00 PM

Lumito publishes investor letter – 2025 in review and the road ahead

Lumito
Regulatory press release12/19/2025, 2:05 PM

KALLELSE TILL EXTRA BOLAGSSTÄMMA I LUMITO AB (PUBL)

Lumito
Regulatory press release12/19/2025, 2:00 PM

Lumitos styrelse föreslår sammanläggning av aktier

Lumito
Regulatory press release12/19/2025, 2:00 PM

The Board of Directors of Lumito proposes a reversed share split

Lumito
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.